Global Live Attenuated Vaccines Market Valued at $30.2 billion in 2025, Set to Grow at a 10.1% CAGR

Live attenuated vaccines market was valued at $30.2 billion in 2025 and is projected to reach $78.6 billion by 2035, growing at a CAGR of 10.1% during the forecast Period (2026-2035). Government immunization programs and global vaccination campaigns significantly promote the adoption of live attenuated vaccines. Their inclusion in routine immunization schedules for both children and adults ensures steady demand and supports consistent market growth. As a reflection of this structured approach to public health, regulatory authorities in major markets actively evaluate and approve key vaccines to maintain robust immunization coverage.

Browse the full report description of “Live Attenuated Vaccines Market Size, Share & Trends Analysis by Product Type (Viral Vaccines, and Bacterial Vaccines), By Indication (Tuberculosis, Measles, Mumps & Rubella (MMR), Rotavirus, Yellow Fever, Oral Polio, Influenza, and Others), By  Route of Administration (Injectable, Oral, and Intranasal), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/live-attenuated-vaccnes-market

For instance, in March 2025, the US Food and Drug Administration (FDA) approved about eight distinct live attenuated vaccines or vaccine formulations for human use in the US. These include well?established vaccines such as measles?mumps?rubella (MMR), varicella, live attenuated influenza vaccine (LAIV), rotavirus vaccines (Rotarix, RotaTeq), yellow fever vaccine, smallpox vaccine (ACAM2000), and combination products like MMRV that bundle several antigens into one dose. This count reflects the primary live attenuated vaccines widely used in public immunization programs and emergency preparedness, each chosen for its proven safety, immunogenicity, and public health impact.

FDA Suspends Chikungunya Vaccine License Over Safety Concerns

• In August?2025, the US Food and Drug Administration (FDA) suspended the biologics license for Ixchiq, a live?attenuated chikungunya vaccine made by Valneva, citing serious safety concerns after reports of multiple serious adverse events, including hospitalizations and at least one death linked to vaccine?associated illness. The agency concluded that, based on available data, the potential risks outweigh the benefits, and continued use could pose a danger to public health.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Indication
  • BY Route of Administration
  • By Distribution Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc., Sanofi, Serum Institute of India (SII), among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Live Attenuated Vaccines Market Report Segment

By Product Type

• Viral Vaccines
• Bacterial Vaccines

By Indication

• Tuberculosis
• Measles, Mumps & Rubella (MMR)
• Rotavirus
• Yellow Fever
• Oral Polio
• Influenza (where applicable)
• Others

By Route of Administration

• Injectable
• Oral
• Intranasal

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Live Attenuated Vaccines Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/live-attenuated-vaccnes-market